Journal article
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
- Abstract:
-
BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with certolizumab pegol that was first published in 2011. OBJECTIVES: To assess the clinical benefits and harms of certolizumab pegol (CDP870) in patients with RA who have not responded well to conventi...
Expand abstract
Actions
Authors
- Journal:
- Cochrane database of systematic reviews More from this journal
- Volume:
- 9
- Pages:
- CD007649
- Publication date:
- 2014-01-01
- DOI:
- EISSN:
-
1469-493X
- Language:
-
English
- Pubs id:
-
pubs:139031
- UUID:
-
uuid:bebb29b0-bc5c-473b-94c9-b01c587d84be
- Local pid:
-
pubs:139031
- Source identifiers:
-
139031
- Deposit date:
-
2012-12-19
Terms of use
- Copyright date:
- 2014
If you are the owner of this record, you can report an update to it here: Report update to this record